Ex Parte Massaro et al - Page 6

              Appeal 2007-0852                                                                                         
              Application 09/919,195                                                                                   
              exemplary compounds of specific disclosed structure” (Br. 11), but they                                  
              have not provided evidence that the cited patents describe antagonists which                             
              are also not specific to at least one other RAR receptor subtype as recited in                           
              claim 13.                                                                                                
                     In University of California v. Eli Lilly & Co., 119 F.3d 1559, 43 USPQ2d                          
              1398 (Fed. Cir. 1997), the court held that claims generically reciting cDNA                              
              encoding vertebrate or mammalian insulin were not adequately described by the                            
              disclosure of cDNA encoding rat insulin.  Id. at 1568, 43 USPQ2d at 1406.  The                           
              court held that                                                                                          
                     a generic statement such as “vertebrate insulin cDNA” or                                          
                     “mammalian insulin cDNA,” without more, is not an adequate written                                
                     description of the genus because it does not distinguish the claimed                              
                     genus from others, except by function.  It does not specifically define                           
                     any of the genes that fall within its definition.  It does not define any                         
                     structural features commonly possessed by members of the genus that                               
                     distinguish them from others.  One skilled in the art therefore cannot,                           
                     as one can do with a fully described genus, visualize or recognize the                            
                     identity of the members of the genus.                                                             
              Id. At 1569, 43 USPQ2d at 1406. The court held that a                                                    
                     A description of a genus of cDNAs may be achieved by means of a                                   
                     recitation of a representative number of cDNAs, defined by nucleotide                             
                     sequence, falling within the scope of the genus or of a recitation of                             
                     structural  features  common  to the  members  of  the  genus,  which                             
                     features constitute a substantial portion of the genus.                                           
              Id.  The court has since clarified that the complete structure of the representative                     
              species does not necessarily have to be described.  See Enzo Biochem v. Gen-Probe                        
              Inc., 323 F.3d 956, 964-65, 63 USPQ2d 1609, 1613 (Fed. Cir. 2002).                                       
                     The instant Specification does not adequately describe the recited genera of                      
              compounds having RARβ antagonist activity for use in the claimed method.  The                            
              Eli Lilly court held that a fully described genus is one for which a person skilled in                   
              the art can “visualize or recognize the identity of the members of the genus.”  Here,                    

                                                         - 6 -                                                         

Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  Next

Last modified: September 9, 2013